Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Co-Founder & CEO Cyriac Roeding and Co-Founder & CSO David Suhy describe the science behind this approach and explain how AI is helping they move closer to the clinic. The first IND filing is scheduled to be late '26 or early '27.